Dr. James T. Zipagan, MD

Dr. Zipagan practices at Monmouth Medical Center Southern Campus in Lakewood, New Jersey, part of RWJBarnabas Health.

Dr. Zipagan's NPI, 1467554527, was assigned on September 1, 2006. Dr. Zipagan holds New Jersey license 25MA35168.

Dr. Zipagan's primary practice is Monmouth Medical Center Southern Campus, at 600 River Ave, Lakewood, NJ 08701 in Ocean County. The practice phone is (732) 363-1900.

Dr. Zipagan's primary practice is Monmouth Medical Center Southern Campus in Lakewood, New Jersey, part of RWJBarnabas Health. Dr. Zipagan is also affiliated with Jersey Shore University Medical Center. The medical group on file is RWJBarnabas Health Medical Group. Dmand AI also links Dr. Zipagan to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zipagan practices, 2 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Zipagan's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dr. Zipagan is licensed in New Jersey.

CMS data shows 448 Medicare services from Dr. Zipagan across 6 procedure codes in 2024, for 403 Medicare patients. Medicare paid $51,966 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 403 Medicare patients who saw Dr. Zipagan in 2024. The largest group is 75 to 84, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 29% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zipagan's median patient age at 66, with 50% women.

In 2024, Dr. Zipagan wrote 101 Medicare Part D claims for 76 patients. 98% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $38 in total drug cost. In 2023, CMS named 28 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Zipagan for performance year 2024, reported as part of a group. Dr. Zipagan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Dr. Zipagan from 2 drug and device companies from 2019 to 2023. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $125.